Biomarker and diagnosis system for colorectal cancer detection

Abstract

The present disclosure provides a biomarker for detecting colorectal cancer and a use thereof. A metabolomics method is used to analyze metabolites with significant differences in urine of patients with colorectal cancer and normal people, such that a series of biomarkers capable of early predicting an occurrence risk of colorectal cancer are screened out, a group of biomarkers are further screened to construct a diagnostic model for colorectal cancer, and the model can be used for conveniently, non-invasively and effectively predicting whether an individual suffers from colorectal cancer, and meets clinical needs.

Dependencies are inferred from the claim text.